Literature DB >> 17561423

Biodistribution in mice and severity of damage in rat lungs following pulmonary delivery of 9-nitrocamptothecin liposomes.

Li-Jun Zhang1, Bin Xing, Jiang Wu, Bai Xu, Xiao-Ling Fang.   

Abstract

This study was designed to investigate in vitro release, in vivo tissue distribution and the damage to the lungs of 9-nitrocamptothecin (9-NC) liposomes. In vitro release of 9-NC from liposomes was carried out in phosphate buffer saline solution (PBS) pH 7.4. The tissue distribution of 9-NC liposomes and 9-NC solution was determined after pulmonary delivery to mice. The tissue distribution of 9-NC liposomes after intravenous administration was also studied. The changes of pulmonary edema index and histology of lungs in rats were investigated to evaluate the severity of the damage after pulmonary delivery. The results showed that 9-NC was continuously released from liposomes in PBS pH 7.4 for 24h at 37 degrees C. After pulmonary delivery, the mean residence time (MRT) of 9-NC liposomes in the lungs was 3.4 times as long as that of 9-NC solution and the total AUC0-t of all tissues in mice of the liposomes was 2.2-fold higher than that of the solution, indicating that the liposomes had sustained-release characteristics. Following intravenous administration and pulmonary delivery, the targeting efficiency (Te) to the lung of 9-NC liposomes was 0.14 and 2.02, respectively, which showed that intratracheal instillation can deliver the drug mainly to the lung and decrease the accumulation of the drug in other tissues at different concentrations. The pulmonary edema index and the histological changes of the lungs in 9-NC liposome group were significantly different from those in 9-NC solution group. The lung damage by liposomes was less severe than that by solution. Pulmonary delivery of 9-NC liposomes could directly deliver the drug to the lung and make the drug accumulate in the lung with sustained-release characteristics, changing the disposition behavior in vivo, decreasing the toxic and side effects on other tissues and reduce the severity of damage to lungs following intratracheal instillation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17561423     DOI: 10.1016/j.pupt.2007.04.002

Source DB:  PubMed          Journal:  Pulm Pharmacol Ther        ISSN: 1094-5539            Impact factor:   3.410


  5 in total

Review 1.  Lipid-based pulmonary delivery system: a review and future considerations of formulation strategies and limitations.

Authors:  Cheng Loong Ngan; Azren Aida Asmawi
Journal:  Drug Deliv Transl Res       Date:  2018-10       Impact factor: 4.617

2.  Rapid lymph accumulation of polystyrene nanoparticles following pulmonary administration.

Authors:  Abdul Khader Mohammad; Lenah K Amayreh; John M Mazzara; Joshua J Reineke
Journal:  Pharm Res       Date:  2012-09-20       Impact factor: 4.200

3.  Exploring targeted pulmonary delivery for treatment of lung cancer.

Authors:  Amit Goel; Sanjula Baboota; Jasjeet K Sahni; Javed Ali
Journal:  Int J Pharm Investig       Date:  2013-01

Review 4.  Pulmonary route of administration is instrumental in developing therapeutic interventions against respiratory diseases.

Authors:  Xue Jin; Ling Song; Chao-Chao Ma; Yan-Chun Zhang; Shui Yu
Journal:  Saudi Pharm J       Date:  2020-11-04       Impact factor: 4.330

Review 5.  Nanotechnology-based inhalation treatments for lung cancer: state of the art.

Authors:  Javed Ahmad; Sohail Akhter; Md Rizwanullah; Saima Amin; Mahfoozur Rahman; Mohammad Zaki Ahmad; Moshahid Alam Rizvi; Mohammad A Kamal; Farhan Jalees Ahmad
Journal:  Nanotechnol Sci Appl       Date:  2015-11-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.